Ponatinib therapy in recurrent Philadelphia chromosome‐positive central nervous system leukemia with T315I mutation after Allo‐HSCT

Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome‐positive (Ph+) leukemia patients who undergo allogeneic hematopoietic stem cell transplantation (allo‐HSCT). The prognosis of patients is dismal for those with a BCR‐ABL T315I mutation, which is resistant to TKIs including second‐generation drugs. We assessed ponatinib for nine patients with recurrent Ph+ CNSL and a T315I mutation after allo‐HSCT,...